|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lian EY, Hyndman BD, Moodley S, Maritan SM
and Mulligan LM: RET isoforms contribute differentially to invasive
processes in pancreatic ductal adenocarcinoma. Oncogene. Sep
3–2020.(Epub ahead of print). View Article : Google Scholar
|
|
3
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bertero L, Massa F, Metovic J, Zanetti R,
Castellano I, Ricardi U, Papotti M and Cassoni P: Eighth edition of
the UICC Classification of Malignant Tumours: An overview of the
changes in the pathological TNM classification criteria-What has
changed and why? Virchows Archiv. 472:519–531. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galon J, Pagès F, Marincola FM, Thurin M,
Trinchieri G, Fox BA, Gajewski TF and Ascierto PA: The immune score
as a new possible approach for the classification of cancer. J
Transl Med. 10:12012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xiang J, Liu L, Wang W, Xu H, Wu C, Xu J,
Liu C, Long J, Ni Q and Yu X: Metabolic tumor burden: A new
promising way to reach precise personalized therapy in PDAC. Cancer
Lett. 359:165–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Jing R, Xu J, Liu K, Xue J, Wen Z
and Li M: Comparative analysis of oncogenes identified by
microarray and RNA-sequencing as biomarkers for clinical prognosis.
Biomark Med. 9:1067–1078. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moon YW, Hajjar J, Hwu P and Naing A:
Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J
Immunother Cancer. 3:512015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harden JL and Egilmez NK: Indoleamine
2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest.
41:738–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshihara K, Shahmoradgoli M, Martínez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martinez-Bosch N, Vinaixa J and Navarro P:
Immune evasion in pancreatic cancer: From mechanisms to therapy.
Cancers (Basel). 10:62018. View Article : Google Scholar
|
|
13
|
Dreyer SB, Chang DK, Bailey P and Biankin
AV: Pancreatic cancer genomes: Implications for clinical management
and therapeutic development. Clin Cancer Res. 23:1638–1646. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Knudsen ES, Vail P, Balaji U, Ngo H,
Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM,
et al: Stratification of pancreatic ductal adenocarcinoma:
Combinatorial genetic, stromal, and immunologic markers. Clin
Cancer Res. 23:4429–4440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Connor AA, Denroche RE, Jang GH, Timms L,
Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA,
Borozan I, et al: Association of distinct mutational signatures
with correlates of increased immune activity in pancreatic ductal
adenocarcinoma. JAMA Oncol. 3:774–783. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu
S, Truitt ML, He N, Ding N, Liddle C, Atkins AR, et al: Stromal
cues regulate the pancreatic cancer epigenome and metabolome. Proc
Natl Acad Sci USA. 114:1129–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia D, Li S, Li D, Xue H, Yang D and Liu
Y: Mining TCGA database for genes of prognostic value in
glioblastoma microenvironment. Aging (Albany NY). 10:592–605. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
GTEx Consortium: Human genomics. The
Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene
regulation in humans. Science. 348:648–660. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network.
Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome
Atlas Research Network: Integrated genomic characterization of
pancreatic ductal adenocarcinoma. Cancer Cell. 32:185–203.e13.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bailey P, Chang DK, Nones K, Johns AL,
Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC,
et al: Genomic analyses identify molecular subtypes of pancreatic
cancer. Nature. 531:47–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang S, He P, Wang J, Schetter A, Tang W,
Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, et al: A
novel MIF signaling pathway drives the malignant character of
pancreatic cancer by targeting NR3C2. Cancer Res. 76:3838–3850.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bhattacharya S, Andorf S, Gomes L, Dunn P,
Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J,
et al: ImmPort: Disseminating data to the public for the future of
immunology. Immunol Res. 58:234–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han
S and Wu A: Bioinformatic profiling identifies an immune-related
risk signature for glioblastoma. Neurology. 86:2226–2234. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bao ZS, Li MY, Wang JY, Zhang CB, Wang HJ,
Yan W, Liu YW, Zhang W, Chen L and Jiang T: Prognostic value of a
nine-gene signature in glioma patients based on mRNA expression
profiling. CNS Neurosci Ther. 20:112–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei C, Liang Q, Li X, Li H, Liu Y, Huang
X, Chen X, Guo Y and Li J: Bioinformatics profiling utilized a nine
immune-related long noncoding RNA signature as a prognostic target
for pancreatic cancer. J Cell Biochem. 120:14916–14927. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barbie DA, Tamayo P, Boehm JS, Kim SY,
Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al:
Systematic RNA interference reveals that oncogenic KRAS-driven
cancers require TBK1. Nature. 462:108–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gentles AJ, Newman AM, Liu CL, Bratman SV,
Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang C, et al: The
prognostic landscape of genes and infiltrating immune cells across
human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kota J, Hancock J, Kwon J and Korc M:
Pancreatic cancer: Stroma and its current and emerging targeted
therapies. Cancer Lett. 391:38–49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dieterich LC and Bikfalvi A: The tumor
organismal environment: Role in tumor development and cancer
immunotherapy. Semin Cancer Biol. 65:197–206. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X, Li Y, Li J, Li L, Zhu H, Chen H,
Kong R, Wang G, Wang Y, Hu J and Sun B: Cell-in-cell phenomenon and
its relationship with tumor microenvironment and tumor progression:
A review. Front Cell Dev Biol. 7:3112019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Y, Lazarus J, Steele NG, Yan W, Lee
HJ, Nwosu ZC, Halbrook CJ, Menjivar RE, Kemp SB, Sirihorachai VR,
et al: Regulatory T cell depletion alters the tumor
microenvironment and accelerates pancreatic carcinogenesis. Cancer
Discov. 10:422–439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sohal DPS, Kennedy EB, Khorana A, Copur
MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C,
O'Reilly EM, Philip PA, et al: Metastatic pancreatic cancer: ASCO
clinical practice guideline update. J Clin Oncol. 36:2545–2556.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wartenberg M, Cibin S, Zlobec I, Vassella
E, Eppenberger-Castori S, Terracciano L, Eichmann MD, Worni M,
Gloor B, Perren A and Karamitopoulou E: Integrated genomic and
immunophenotypic classification of pancreatic cancer reveals three
distinct subtypes with prognostic/predictive significance. Clin
Cancer Res. 24:4444–4454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rückert F, Dawelbait G, Winter C, Hartmann
A, Denz A, Ammerpohl O, Schroeder M, Schackert HK, Sipos B, Klöppel
G, et al: Examination of apoptosis signaling in pancreatic cancer
by computational signal transduction analysis. PLoS One.
5:e122432010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haider S, Wang J, Nagano A, Desai A,
Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T, Marshall JF,
Kocher HM, et al: A multi-gene signature predicts outcome in
patients with pancreatic ductal adenocarcinoma. Genome Med.
6:1052014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tang D, Wu Q, Yuan Z, Xu J, Zhang H, Jin
Z, Zhang Q, Xu M, Wang Z, Dai Z, et al: Identification of key
pathways and genes changes in pancreatic cancer cells (BXPC-3)
after cross-talk with primary pancreatic stellate cells using
bioinformatics analysis. Neoplasma. 66:681–693. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qian X, Chen Z, Chen SS, Liu LM and Zhang
AQ: Integrated analyses identify immune-related signature
associated with Qingyihuaji formula for treatment of pancreatic
ductal adenocarcinoma using network pharmacology and weighted gene
co-expression network. J Immunol Res. 2020:75036052020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lundberg M, Krogvold L, Kuric E,
Dahl-Jorgensen K and Skog O: Expression of interferon-stimulated
genes in insulitic pancreatic islets of patients recently diagnosed
with type 1 diabetes. Diabetes. 65:3104–3110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Carey CM, Govande AA, Cooper JM, Hartley
MK, Kranzusch PJ and Elde NC: Recurrent loss-of-function mutations
reveal costs to OAS1 antiviral activity in primates. Cell Host
Microbe. 25:336–343.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mandal S, Abebe F and Chaudhary J: 2′-5′
oligoadenylate synthetase 1 polymorphism is associated with
prostate cancer. Cancer. 117:5509–5518. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Moerdyk-Schauwecker M, Shah NR, Murphy AM,
Hastie E, Mukherjee P and Grdzelishvili VZ: Resistance of
pancreatic cancer cells to oncolytic vesicular stomatitis virus:
Role of type I interferon signaling. Virology. 436:221–234. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ito M, Shichijo S, Tsuda N, Ochi M,
Harashima N, Saito N and Itoh K: Molecular basis of T cell-mediated
recognition of pancreatic cancer cells. Cancer Res. 61:2038–2046.
2001.PubMed/NCBI
|
|
48
|
Escorcia FE, Houghton JL, Abdel-Atti D,
Pereira PR, Cho A, Gutsche NT, Baidoo KE and Lewis J: ImmunoPET
predicts response to Met-targeted radioligand therapy in models of
pancreatic cancer resistant to met kinase inhibitors. Theranostics.
10:151–165. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan
C, Wu Y, Li X, Li X, Li G, et al: Function of the c-Met receptor
tyrosine kinase in carcinogenesis and associated therapeutic
opportunities. Mol Cancer. 17:452018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yamaoka T, Kusumoto S, Ando K, Ohba M and
Ohmori T: Receptor tyrosine kinase-targeted cancer therapy. Int J
Mol Sci. 19:34912018. View Article : Google Scholar
|
|
51
|
Giovannetti E, van der Borden CL, Frampton
AE, Ali A, Firuzi O and Peters GJ: Never let it go: Stopping key
mechanisms underlying metastasis to fight pancreatic cancer. Semin
Cancer Biol. 44:43–59. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Moosavi F, Giovannetti E, Saso L and
Firuzi O: HGF/MET pathway aberrations as diagnostic, prognostic,
and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci.
56:533–566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hu CY, Xu XM, Hong B, Wu ZG, Qian Y, Weng
TH, Liu YZ, Tang TM, Wang MH and Yao HP: Aberrant RON and MET
co-overexpression as novel prognostic biomarkers of shortened
patient survival and therapeutic targets of tyrosine kinase
inhibitors in pancreatic cancer. Front Oncol. 9:13772019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
De Simone M, Arrigoni A, Rossetti G,
Gruarin P, Ranzani V, Politano C, Bonnal RJP, Provasi E, Sarnicola
ML, Panzeri I, et al: Transcriptional landscape of human tissue
lymphocytes unveils uniqueness of tumor-infiltrating T regulatory
cells. Immunity. 45:1135–1147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ritvo PG, Churlaud G, Quiniou V, Florez L,
Brimaud F, Fourcade G, Mariotti-Ferrandiz E and Klatzmann D:
Tfr cells lack IL-2Rα but express decoy IL-1R2 and
IL-1Ra and suppress the IL-1-dependent activation of Tfh
cells. Sci Immunol. 2:eaan03682017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Plitas G, Konopacki C, Wu K, Bos PD,
Morrow M, Putintseva EV, Chudakov DM and Rudensky AY: Regulatory T
cells exhibit distinct features in human breast cancer. Immunity.
45:1122–1134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Madouri F, Barada O, Kervoaze G, Trottein
F, Pichavant M and Gosset P: Production of interleukin-20 cytokines
limits bacterial clearance and lung inflammation during infection
by Streptococcus pneumoniae. EBioMedicine. 37:417–427. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Omarini C, Bettelli S, Caprera C,
Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L,
Kaleci S, et al: Clinical and molecular predictors of long-term
response in HER2 positive metastatic breast cancer patients. Cancer
Biol Ther. 19:879–886. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Baird AM, Gray SG and O'Byrne KJ: IL-20 is
epigenetically regulated in NSCLC and down regulates the expression
of VEGF. Eur J Cancer. 47:1908–1918. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gao F, Zhao ZL, Zhao WT, Fan QR, Wang SC,
Li J, Zhang YQ, Shi JW, Lin XL, Yang S, et al: miR-9 modulates the
expression of interferon-regulated genes and MHC class I molecules
in human nasopharyngeal carcinoma cells. Biochem Biophys Res
Commun. 431:610–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Manzo T, Prentice BM, Anderson KG, Raman
A, Schalck A, Codreanu GS, Nava Lauson CB, Tiberti S, Raimondi A,
Jones MA, et al: Accumulation of long-chain fatty acids in the
tumor microenvironment drives dysfunction in intrapancreatic CD8+ T
cells. J Exp Med. 217:e201919202020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hessmann E, Buchholz SM, Demir IE, Singh
SK, Gress TM, Ellenrieder V and Neesse A: Microenvironmental
determinants of pancreatic cancer. Physiol Rev. 100:1707–1751.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Junttila MR and de Sauvage FJ: Influence
of tumour micro-environment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Petitprez F, Vano YA, Becht E, Giraldo NA,
de Reyniès A, Sautès-Fridman C and Fridman WH: Transcriptomic
analysis of the tumor microenvironment to guide prognosis and
immunotherapies. Cancer Immunol Immunother. 67:981–988. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mahajan UM, Langhoff E, Goni E, Costello
E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback
S, et al: Immune cell and stromal signature associated with
progression-free survival of patients with resected pancreatic
ductal adenocarcinoma. Gastroenterology. 155:1625–1639.e2. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu
CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, et
al: Impact of immune and stromal infiltration on outcomes following
bladder-sparing trimodality therapy for muscle-invasive bladder
cancer. Eur Urol. 76:59–68. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Jusakul A, Cutcutache I, Yong CH, Lim JQ,
Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, et
al: Whole-genome and epigenomic landscapes of etiologically
distinct subtypes of cholangiocarcinoma. Cancer Discov.
7:1116–1135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rohr-Udilova N, Klinglmüller F,
Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F,
Timelthaler G, Oberhuber G, Pinter M, et al: Deviations of the
immune cell landscape between healthy liver and hepatocellular
carcinoma. Sci Rep. 8:62202018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xiong Y, Liu L, Xia Y, Qi Y, Chen Y, Chen
L, Zhang P, Kong Y, Qu Y, Wang Z, et al: Tumor infiltrating masT
cells determine oncogenic HIF-2alpha-conferred immune evasion in
clear cell renal cell carcinoma. Cancer Immunol Immunother.
68:731–741. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen B, Khodadoust MS, Liu CL, Newman AM
and Alizadeh AA: Profiling tumor infiltrating immune cells with
CIBERSORT. Methods Mol Biol. 1711:243–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tahkola K, Mecklin JP, Wirta EV, Ahtiainen
M, Helminen O, Böhm J and Kellokumpu I: High immune cell score
predicts improved survival in pancreatic cancer. Virchows Archiv.
472:653–665. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bense RD, Sotiriou C, Piccart-Gebhart MJ,
Haanen JBAG, van Vugt MATM, de Vries EGE, Schröder CP and Fehrmann
RSN: Relevance of tumor-infiltrating immune cell composition and
functionality for disease outcome in breast cancer. J Natl Cancer
Inst. 109:djw1922017. View Article : Google Scholar
|
